SNGX - Soligenix, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.55
-0.09 (-5.49%)
At close: 4:00PM EDT

1.54 -0.01 (-0.65%)
After hours: 7:58PM EDT

Stock chart is not supported by your current browser
Previous Close1.64
Open1.64
Bid1.55 x 2200
Ask1.58 x 800
Day's Range1.51 - 1.69
52 Week Range0.91 - 3.70
Volume506,518
Avg. Volume277,500
Market Cap27.408M
Beta0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.91
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
Trade prices are not sourced from all markets
  • Zacks Small Cap Research7 days ago

    SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL?

    Soligenix (SNGX) is a late-stage biopharmaceutical company with two Phase III candidates. While we are waiting for the interim analysis of SGX301 in the coming month, we recently interviewed Dr. Richard C. Straube, Sr. VP & Chief Medical Officer of Soligenix (SNGX) with respect to the prospect of this late stage candidate. Following are the summary of what we get from Dr. Richard Straube.

  • PR Newswire8 days ago

    NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program

    PRINCETON, N.J. , Sept. 13, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

  • PR Newswire16 days ago

    Soligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry

    PRINCETON, N.J., Sept. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the 25th Annual NewsMakers in the Biotech Industry on Friday, September 7 at 11:30AM ET.

  • PR Newswire17 days ago

    Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine

    PRINCETON, N.J., Sept. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of extended stability studies for RiVax® showing up to 100% protection in mice even after 12 months storage at 40 degrees Celsius (104 degrees Fahrenheit), as well as the identification of a potential in vitro stability indicating assay, critical to adequately confirming long-term shelf-life of the vaccine.  The article, entitled "Thermal Stability and Epitope Integrity of a Lyophilized Ricin Toxin Subunit Vaccine", is published in the journal Vaccine online and is available here.

  • PR Newswire23 days ago

    Soligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

    PRINCETON, N.J., Aug. 29, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical and clinical data illustrating the potential utility of the Innate Defense Regulator technology in the treatment of infectious disease in a poster session at the upcoming European Society of Clinical Microbiology and Infectious Diseases / American Society of Microbiology Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance on September 4 - 7, 2018 to be held in Lisbon, Portugal.

  • PR Newswirelast month

    Soligenix Receives US Patent for Improved Production of Synthetic Hypericin

    Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J. , Aug. 22, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

  • PR Newswirelast month

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 13, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • PR Newswirelast month

    Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results

    PRINCETON, N.J., Aug. 8, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the second quarter ended June 30, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "Our primary focus remains the quality execution of our two pivotal Phase 3 clincial programs.  We are continuing to enroll patients in our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin), where we anticipate the interim analysis in the October 2018 timeframe and final topline results in the first half of 2019.

  • PR Newswire2 months ago

    Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada

    PRINCETON, N.J., July 26, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing potential immune correlates of protection to facilitate vaccine approval under the Food and Drug Administration (FDA) Animal Rule. The presentation will be given at the upcoming 31st Annual Congress on Vaccines, Clinical Trials & B2B Conference on July 27-28, 2018 to be held at the Executive Airport Plaza Hotel & Conference Centre, Richmond, BC, Canada.

  • PR Newswire2 months ago

    Soligenix Announces Appointment of Mark Pearson to its Board of Directors

    PRINCETON, N.J. , July 24, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • PR Newswire2 months ago

    Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., July 19, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.

  • PR Newswire2 months ago

    Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation

    PRINCETON, N.J., July 9, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of allowance for European (application No. 12786638.2) and Canadian (application No. 2836273) patent applications further extending protection around ThermoVax® including coverage of the Company's ricin toxin vaccine, RiVax®. The issued patent is complementary to previous patents, including US patents 8,444,991 granted on May 21, 2013 and 8,808,710 granted on August 19, 2014, that include claims for methods of making stabilized vaccines and their attendant compositions.  In this new patent, the main claims cover formulations of Soligenix's proprietary thermostabilized ricin toxin vaccine, RiVax®.  The thermostable formulation of RiVax® has been shown to be stable for at least 12 months at temperatures up to 40 degrees Celsius (104 degrees Fahrenheit) and to provide 100% protection to non-human primates exposed to aerosol ricin challenge in preclinical studies.

  • Zacks Small Cap Research2 months ago

    SNGX: New Financing Boosts Balance Sheet

    In early July, Soligenix (SNGX) closed an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase up to an aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, the underwriters partially exercised the over-allotment to purchase additional warrants to purchase 466,019 shares of common stock. Gross proceeds to Soligenix from this offering were approximately $8 million.

  • PR Newswire3 months ago

    Soligenix Announces Closing of $8,000,000 At The Market Public Offering

    PRINCETON, N.J., July 2, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase up to an aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, the underwriters partially exercised the over-allotment to purchase additional warrants to purchase 466,019 shares of common stock. Gross proceeds to Soligenix, Inc. from this offering are approximately $8,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Soligenix, Inc.

  • PR Newswire3 months ago

    Soligenix, Inc. Prices $8,000,000 Public Offering At The Market

    PRINCETON, N.J., June 28, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase 3,106,796 shares of common stock  at a combined public offering price of $1.03 per share and warrant. The warrants will have an initial per share exercise price of $2.25, subject to customary adjustment, are exercisable immediately and will expire forty-two (42) months from the date of issuance. The gross proceeds to Soligenix, Inc. from this offering are expected to be approximately $8,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • PR Newswire4 months ago

    Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia

    PRINCETON, N.J., June 4, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting preclinical and clinical data illustrating the potential utility of the Innate Defense Regulator technology in the treatment of infectious disease  at the upcoming American Society of Microbiology Microbe Conference on June 7-11, 2018 to be held at the Georgia World Congress Center, Atlanta, GA. Host-Directed Innate Defense Regulators with Preclinical and Clinical Proof of Concept attended by Dr. Oreola Donini, Chief Scientific Officer, Soligenix, Inc., on June 8, 2018 from 11:00 AM - 1:00 PM local time, Halls B2-B5.

  • Soligenix Inc’s (NASDAQ:SNGX) Shift From Loss To Profit
    Simply Wall St.4 months ago

    Soligenix Inc’s (NASDAQ:SNGX) Shift From Loss To Profit

    Soligenix Inc’s (NASDAQ:SNGX): Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company’s loss has recently broadened sinceRead More...

  • Zacks Small Cap Research4 months ago

    SNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola Vaccine

    Recently, Congo reported the outbreak of Ebola, with at least 32 suspected, probable or confirmed cases of the disease since April 4, including 18 deaths. The WHO is moving quickly this time, and hopes to use Ebola vaccine to stem the outbreak in Congo. The vaccine proved to be highly effective in the 2015 trial that involved more than 5,800 people, none of whom developed Ebola nine days or more after vaccination.

  • PR Newswire4 months ago

    Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results

    PRINCETON, N.J., May 11, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the first quarter ended March 31, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are actively enrolling patients in our pivotal double-blind, placebo-controlled, multinational Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy, and expect final results in the second half of 2019.

  • PR Newswire5 months ago

    Soligenix to Present at the NYC Oncology Investor Conference 2018

    PRINCETON, N.J., May 7, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Financial Officer, Karen Krumeich, will deliver a corporate presentation at the NYC Oncology Investor Conference 2018 on Tuesday, May 8 at 2:00PM ET. The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Wilson Sonsini Law Firm, Torreya Partners, and Marcum is the leading conference for early-stage private and public cancer investing.   For more information about the conference, please refer to the conference website.

  • PR Newswire6 months ago

    Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning

    PRINCETON, N.J., March 22, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products, has granted orphan drug designation to the Company's recombinant modified ricin toxin A-chain subunit (the active pharmaceutical ingredient in RiVax®) for the prevention of ricin poisoning.  RiVax® has previously been granted orphan drug designation from the US Food and Drug Administration (FDA).

  • PR Newswire6 months ago

    Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results

    PRINCETON, N.J., March 15, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2017. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "In the third quarter of 2017, we initiated a pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy.

  • PR Newswire6 months ago

    Soligenix to Present at the 12th Annual International Partnering Conference Bio-Europe Spring

    PRINCETON, N.J., March 13, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Financial Officer, Karen Krumeich, will deliver a corporate presentation at the 12th Annual International Partnering Conference Bio-Europe Spring in Amsterdam, Wednesday, March 14 at 10:00 AM GMT. For more information about the 12th Annual International Partnering Conference Bio-Europe Spring, please refer to the conference website.

  • PR Newswire8 months ago

    Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., Jan. 25, 2018 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below.

  • ACCESSWIRE9 months ago

    Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis

    LONDON, UK / ACCESSWIRE / January 04, 2018 / Active-Investors.com has just released a free research report on Soligenix, Inc. (NASDAQ: SNGX ). If you want access to this report all you need to do is sign ...